“Excited to witness the primary batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune. The vaccine has nice potential to guard our future generations beneath the age of 18. Trials are ongoing. Nicely completed workforce @seruminstindia,” Poonawalla mentioned in a tweet.
In March this yr, he had mentioned that the scientific trials of Covovax vaccine have begun in India and the corporate hopes to launch it by September this yr.
In August 2020, American vaccine firm Novavax Inc had introduced a licence settlement with SII for the event and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income international locations and India.
In January this yr, the Serum Institute had rolled out Covishield vaccine within the nation. It had entered right into a collaboration with the College of Oxford and
to fabricate the vaccine.
Excited to witness the primary batch of Covovax (developed by @Novavax) being manufactured this week at our facility… https://t.co/yAM9yH2JHt
— Adar Poonawalla (@adarpoonawalla) 1624615476000